DK2406280T3 - Biologiske materialer og anvendelser deraf - Google Patents

Biologiske materialer og anvendelser deraf

Info

Publication number
DK2406280T3
DK2406280T3 DK10722160.8T DK10722160T DK2406280T3 DK 2406280 T3 DK2406280 T3 DK 2406280T3 DK 10722160 T DK10722160 T DK 10722160T DK 2406280 T3 DK2406280 T3 DK 2406280T3
Authority
DK
Denmark
Prior art keywords
applications
biological materials
biological
materials
Prior art date
Application number
DK10722160.8T
Other languages
English (en)
Inventor
Brian Maurice John Foxwell
Kim Suzanne Midwood
Original Assignee
Imp Innovations Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imp Innovations Ltd filed Critical Imp Innovations Ltd
Application granted granted Critical
Publication of DK2406280T3 publication Critical patent/DK2406280T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Rehabilitation Therapy (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
DK10722160.8T 2009-03-13 2010-03-15 Biologiske materialer og anvendelser deraf DK2406280T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0904355.5A GB0904355D0 (en) 2009-03-13 2009-03-13 Biological materials and uses thereof
PCT/GB2010/000460 WO2010103289A1 (en) 2009-03-13 2010-03-15 Biological materials and uses thereof

Publications (1)

Publication Number Publication Date
DK2406280T3 true DK2406280T3 (da) 2014-07-28

Family

ID=40637300

Family Applications (1)

Application Number Title Priority Date Filing Date
DK10722160.8T DK2406280T3 (da) 2009-03-13 2010-03-15 Biologiske materialer og anvendelser deraf

Country Status (18)

Country Link
US (1) US20130045212A1 (da)
EP (3) EP2754668B1 (da)
JP (1) JP5847590B2 (da)
CN (1) CN102712686B (da)
AU (2) AU2010222708B2 (da)
BR (1) BRPI1009819A2 (da)
CA (1) CA2754945C (da)
CY (1) CY1115463T1 (da)
DK (1) DK2406280T3 (da)
ES (1) ES2491617T3 (da)
GB (1) GB0904355D0 (da)
HK (1) HK1199888A1 (da)
HR (1) HRP20140710T1 (da)
PL (1) PL2406280T3 (da)
PT (1) PT2406280E (da)
SI (1) SI2406280T1 (da)
SM (1) SMT201400120B (da)
WO (1) WO2010103289A1 (da)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180022792A9 (en) * 2009-03-13 2018-01-25 Karen Foxwell Biological Materials and Uses Thereof
BR112014014295A2 (pt) * 2011-12-12 2017-06-13 Isis Innovation método para determinar um estado de artrite reumatoide, kit para a determinação o estado de artrite reumatoide erosiva de um indivíduo, usos de tenancina-c, e de uma determinação do nível de tenascina-c, e, métodos para tratar uma condição inflamatória, e uma artrite reumatoide
US20130297023A1 (en) * 2012-05-07 2013-11-07 Hee-Jeong Im Sampen Methods and Devices For Treating Intervertebral Disc Disease
GB2526898A (en) * 2014-01-13 2015-12-09 Imp Innovations Ltd Biological materials and therapeutic uses thereof
GB201414021D0 (en) * 2014-08-07 2014-09-24 Nascient Ltd Biological materials and uses thereof
GB201517184D0 (en) * 2015-09-29 2016-02-10 Imp Innovations Ltd Biological materials and uses thereof
GB201602414D0 (en) * 2016-02-10 2016-03-23 Nascient Ltd Biological materials and uses thereof
GB201616596D0 (en) * 2016-09-29 2016-11-16 Nascient Limited Epitope and antibodies

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB9122820D0 (en) * 1991-10-28 1991-12-11 Wellcome Found Stabilised antibodies
SE9400088D0 (sv) 1994-01-14 1994-01-14 Kabi Pharmacia Ab Bacterial receptor structures
US6124260A (en) * 1998-09-30 2000-09-26 Cedars-Sinai Medical Center Inhibition of smooth muscle cell migration by Tenascin-C peptides
JP3646159B2 (ja) * 2001-02-08 2005-05-11 国立大学法人三重大学 抗テネイシンｃモノクローナル抗体及び当該抗体を産生するハイブリドーマ
AU2003258134A1 (en) * 2002-08-09 2004-02-25 Applera Corporation Lung cancer target proteins and use thereof
JP2004217546A (ja) * 2003-01-10 2004-08-05 Japan Science & Technology Agency 標識化抗テネイシンｃモノクローナル抗体
WO2005009366A2 (en) * 2003-07-24 2005-02-03 Cornell Research Foundation, Inc. Restoring vascular function
WO2008154008A1 (en) * 2007-06-11 2008-12-18 The Scripps Research Institute Methods and compositions for inhibiting toll-like receptor mediated immune responses

Also Published As

Publication number Publication date
EP2406280B1 (en) 2014-05-14
EP3392269B1 (en) 2021-10-27
CA2754945C (en) 2020-03-10
WO2010103289A1 (en) 2010-09-16
PT2406280E (pt) 2014-08-28
SMT201400120B (it) 2014-11-10
EP2754668B1 (en) 2018-05-09
HRP20140710T1 (hr) 2014-09-26
EP3392269A1 (en) 2018-10-24
CN102712686B (zh) 2017-10-17
CA2754945A1 (en) 2010-09-16
JP2012520278A (ja) 2012-09-06
EP2754668A2 (en) 2014-07-16
US20130045212A1 (en) 2013-02-21
AU2010222708A1 (en) 2011-10-06
SI2406280T1 (sl) 2014-09-30
GB0904355D0 (en) 2009-04-29
PL2406280T3 (pl) 2014-11-28
AU2010222708B2 (en) 2014-07-24
JP5847590B2 (ja) 2016-01-27
HK1199888A1 (en) 2015-07-24
ES2491617T3 (es) 2014-09-08
CN102712686A (zh) 2012-10-03
EP2406280A1 (en) 2012-01-18
CY1115463T1 (el) 2017-01-04
BRPI1009819A2 (pt) 2016-11-16
AU2014213514A1 (en) 2014-09-04
AU2014213514B2 (en) 2016-07-14
EP2754668A3 (en) 2014-07-30

Similar Documents

Publication Publication Date Title
DK3292874T3 (da) Anti-mesothelin-immunkonjugater og anvendelser deraf
DK2913344T3 (da) Specifikke bindingsproteiner og anvendelser deraf
DK3339323T3 (da) Anti-n3pglu-amyloid-beta-peptid-antistoffer og anvendelser deraf
DK2139490T3 (da) Diazo-bicykliske smac-mimetiske stoffer og anvendelser deraf
DK2209806T3 (da) Anti-hepcidin-antistoffer og anvendelser deraf
DK2648742T3 (da) Formuleringer indeholdende saponiner og anvendelser deraf
DK2352509T3 (da) Hla-g-proteiner og farmaceutiske anvendelser deraf
DK3091034T3 (da) Anti-CD40-antistoffer og anvendelser deraf
DK2786762T3 (da) Kovalente diabodies og anvendelser deraf
DK2118140T3 (da) Humancytomegalovirus-neutraliserende antistoffer og anvendelse deraf
DK2605789T3 (da) Modificerede relaxinpolypeptider og anvendelser deraf
DK2068887T3 (da) SP35-antistoffer og anvendelser heraf
DK3338790T3 (da) Oligopeptid-forbindelser og anvendelser deraf
DK2328931T3 (da) Selektive anti-hepcidin-25-antistoffer og anvendelser deraf
DK2142529T3 (da) Trpv1-antagonister og anvendelser deraf
DK2170827T3 (da) Indolin-2-oner og aza-indolin-2-oner
DK2170287T3 (da) Mikropartikler omfattende PCL og anvendelser deraf
DK2240203T3 (da) Alfa5-beta1-antistoffer og deres anvendelser
DK2805746T3 (da) Alkylamido-forbindelser og anvendelser deraf
GB201011771D0 (en) Biological material and particular uses thereof
DK2190991T3 (da) SDF-1-Bindende nucleinsyrer og anvendelsen deraf
DK2406280T3 (da) Biologiske materialer og anvendelser deraf
DK2475649T3 (da) Indenonderivat og farmaceutisk sammensætning omfattende samme
GB0904825D0 (en) Biological materials and uses thereof
DK2274619T3 (da) Slimhindereceptor og anvendelser deraf